In this article the authors used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine.

In this article the authors conducted a study involving adults (≥50 years of age) with COVID-19–like illness who underwent molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

In this article the authors extracted data for the period from July 30 through August 31, 2021, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (i.e., had received two doses of BNT162b2) at least 5 months earlier.

The latest EAN webinar, on 'Biomarker-based etiological diagnosis of mild cognitive impairment and mild dementia' takes place on 28 October

With so few chances for EAN staff and members to meet in person, we decided to introduce the team behind the scenes. First up are Marson, from the Congress Department, and Simon, from the Communications Department.

EAN Secretary General, Elena Moro, provides an update on membership-related issues, including a range of new benefits for EAN members.

For October 2021, we have selected: Spelman T. el al Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

For October 2021, we have selected: Lopez Bernal J. et al, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant: test-negative case–control study.

Prof. Gennarina Arabia, Member of the EAN Task Force on Gender and Diversity Issues in Neurology interviews Prof. Giovannella Baggio.

Follow-up interview with Dr. Prashanth LK of the Parkinson's Disease & Movement Disorders Clinic, Bangalore

Alzheimer Europe has co-authored a paper published in Alzheimer's & Dementia: Translational Research & Clinical Interventions on identifying relevant outcomes in the progression of Alzheimer's disease

Registration is now open for the two-day Brain Innovation Days event, to be held physically in Brussels, Belgium, on 12-13 October.

EPICLUSTER will hold its 3rd activity on Accelerating Patient Involvement in European Epilepsy Research on 6 October from 9:30 to 13:00 CET

Call from the European Commission for a member representing health professionals and one alternate for the EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

Breaking News by Dementia and cognitive disorders Panel